
|Videos|January 29, 2016
Dr. David Reardon on Targeting Brain Tumors and Monitoring Resistances
Author(s)David Reardon, MD
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses identifying certain characteristics in a patient's brain tumor in order to administer better treatment.
Advertisement
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses identifying certain characteristics in a patient's brain tumor in order to administer better treatment. Reardon says medical professionals should identify the key drivers in a patient's tumor and select the therapy, or combination therapies, that would best target those traits.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5







































